Pancreatic Cancer

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating stage 4 pancreatic cancer. A clinical trial showed prolongation of life in many patients.

Go to full article published by Good News Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from WebMD curated by Editor in Chief George Lundberg, MD, who notes: 

An aggressive 3-part approach may offer hope for some patients with stage 4 pancreatic cancer.

Go to full article published by WebMD.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.

Go to full article published by The Cancer Letter.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Molecularly matched treatment for pancreatic cancer may extend life for some patients.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.

Go to full paper published in Annals of Surgery.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Philadelphia Inquirer curated by Editor in Chief George Lundberg, MD, who notes: 

A new Pennsylvania law requires insurance coverage for use of FDA-approved best drugs first, rather than only after failing with a cheaper alternative.

Go to full article published by The Philadelphia Inquirer.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

Go to full paper published in Nature.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from the American Society of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

For now, the only definite preventive measures vulnerable patients with cancer can use for themselves and their families are scrupulous social distancing and enhanced personal hygiene; i.e., wash your hands. For more details, ASCO is an authoritative source:

Go to full article published by the American Society of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.